Definitely as interesting point tkrik. Just how do they know?

We could have a 250 lb man taking "C" and a 125 lb women. Is the fat level the same for injection distribution purposes?

Or what about one who metabolizes an oral drug quickly, and maybe one who absorbs drugs slowly. The ideas on this are endless.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Speaking of "C", there is a new clinical trial on "C". It will consist of two different formulations. Maybe pain and injection site reactions will be stopped.

Safety of New Formulation of Glatiramer Acetate (Song)

Purpose

The purpose of this study is to compare injection-site reactions and pain associated with injections of the approved formulation of Glatiramer Acetate (GA) versus investigational formulation of GA. In addition, the investigators will evaluate the side effects of the two formulations of GA.

Study Start Date: July 2009
Estimated Study Completion Date: November 2009
Estimated Primary Completion Date: November 2009 (Final data collection date for primary outcome measure)

http://www.clinicaltrials.gov/ct2/sh...s=teva&rank=15